Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries.
Chaitanya DuttJoao Eduardo Nunes SallesShashank JoshiTiny NairSubhankar ChowdhuryAmbrish MithalViswanathan MohanRavi KasliwalSatyawan SharmaJan TijssenNikhil TandonPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2022)
The epidemic of obesity or adiposity-based chronic diseases presents a significant challenge with the rising prevalence of morbidities and mortality due to atherosclerotic cardiovascular diseases (ASCVD), especially in low- and middle-income countries (LMIC). The underlying pathophysiology of metabolic inflexibility is a common thread linking insulin resistance to cardiometabolic-based chronic disease (CMBCD), including dysglycemia, hypertension, and dyslipidemia progressing to downstream ASCVD events. The complex CMBCD paradigm in the LMIC population within the socio-economic and cultural context highlights considerable heterogeneity of disease predisposition, clinical patterns, and socio-medical needs. This review intends to summarize the current knowledge of CMBCD. We describe recently established or emerging trends for managing risk factors, assessment tools for evaluating ASCVD risk, and various pharmacological and non-pharmacological measures particularly relevant for LMICs. A CMBCD model positions insulin resistance and β-cell dysfunction at the summit of the disease spectrum may improve outcomes at a lower cost in LMICs. Despite identifying multiple pathophysiologic disturbances constituting CMBCD, a large percentage of the patient at risk for ASCVD remains undefined. Targeting dysglycemia, dyslipidemia, and hypertension using antihypertensive, statins, anti-glycemic, and antiplatelet agents has reduced the incidence of ASCVD. Thus, primordial prevention targeting pathophysiological changes that cause abnormalities in adiposity and primary prevention by detecting and managing risk factors remains the foundation for CMBCD management. Therefore, targeting pathways that address mitochondrial dysfunction would exert a beneficial effect on metabolic inflexibility that may potentially correct insulin resistance, β cell dysfunction and, consequently, would be therapeutically effective across the entire continuum of CMBCD.
Keyphrases
- insulin resistance
- risk factors
- blood pressure
- metabolic syndrome
- adipose tissue
- type diabetes
- single cell
- high fat diet
- high fat diet induced
- skeletal muscle
- polycystic ovary syndrome
- cardiovascular disease
- healthcare
- cancer therapy
- glycemic control
- cell therapy
- oxidative stress
- case report
- cardiovascular risk factors
- physical activity
- stem cells
- bone marrow
- drug delivery
- coronary artery disease
- germ cell